Seoul, South Korea, September 4, 2024 – Federal Express Corporation, one of the world’s largest express transportation companies, has received the ‘Innovation in Clinical Supply Chain Logistics’ award at the Korea Biopharma Excellence Awards (KBEA) 2024[1]. This prestigious recognition highlights the company’s pioneering contributions and leadership in transforming the logistics landscape for the biopharmaceutical sector in South Korea and beyond.
“FedEx is deeply honored to receive this award, which is a testament to our relentless commitment to excellence and innovation in the biopharmaceutical logistics field,” said Wonbin Park, managing director, FedEx Korea. “With the aging population and growing focus on health, the healthcare industry is rapidly expanding, making pharmaceutical and biotech logistics a critical component. Moreover, the increasing prevalence of precision medicines has highlighted the importance of cold chain logistics. FedEx strives to support these market changes by leveraging advanced technologies, coupled with our global expertise and extensive network, to make supply chains smarter for everyone. We are committed to facilitating rapid and secure delivery of clinical supplies knowing there’s a patient at the end of every delivery.”
Organized by IMAPAC, KBEA seeks to give recognition to exceptional biopharma experts, organizations, and technologies that drive excellence in biopharmaceutical development and manufacturing in South Korea. The winners are determined based on the results of more than 10,000 votes from South Korea and East Asia biopharma communities.
For decades, FedEx has been building its healthcare capabilities, including its dedicated healthcare team and extensive cold chain network to ship vaccines, biologics, and medical aid all over the world. With a global network of more than 680 aircraft and 200,000 vehicles, and three Life Science Centers in Asia Pacific including South Korea, Japan, and Singapore, FedEx facilitates the movement of healthcare shipments using temperature-controlled solutions and real-time monitoring and intervention through FedEx Surround® to help protect shipment integrity. The company’s dedicated service ‘FedEx Clinical Care’ provides an end-to-end shipping solution designed to transport temperature-sensitive biological samples, medical kits and investigational medicinal products (IMP) at the exact speed and temperature to ensure the safety and compliance of these healthcare shipments.
FedEx was recently named the ‘Overall Logistics & Supply Chain Management Supplier of the Year’ and won the ‘Best Logistics & Supply Chain Management Supplier Award: Last Mile Implementation’ at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2024 by IMAPAC.
FedEx remains committed to continuous innovation and collaboration with industry partners to further enhance its logistics solutions and meet the evolving needs of the global healthcare industry. For more insights on healthcare logistics, please visit FedEx Business Insights.
[1] Korea Biopharma Excellence Awards 2024 – Biopharma Awards (imapac.com)